PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Pack
Likely the first ever clinical study of this magnitude to directly assess ri...
2018-06-17
文传商讯
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relap
81% overall response rate and 40% complete response rate by investigator ass...
2017-12-13
文传商讯
Boehringer Ingelheim presents phase III results demonstrating clinical
Pivotal Phase III study results for biosimilar candidate BI 695501 will be p...
2017-06-16
文传商讯
New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores c
Promising efficacy and safety profile of olmutinib* (BI 1482694) is reaffirm...
2016-06-07
文传商讯
